NasdaqGS:INCYBiotechs
How Q2 Beat, Opzelura Demand and Niktimvo Approval At Incyte (INCY) Has Changed Its Investment Story
Incyte recently reported past second-quarter 2026 results that exceeded earnings and revenue expectations, supported by strong demand for Jakafi and Opzelura, and raised its 2026 net product revenue guidance.
The FDA’s approval of Niktimvo for chronic graft-versus-host disease adds another commercial therapy to Incyte’s portfolio, potentially broadening its revenue base beyond Jakafi.
Next, we’ll explore how the raised 2026 revenue guidance, underpinned by Opzelura demand, reshapes Incyte’s...